Effects of thalidomide on long-term bone marrow cultures from patients with myelodysplastic syndromes: Induction of IL-10 expression in the stromal layers

Leukemia Research

Volumn 35, Issue 8, 2011, Pages 1102-1107

  Lazarini, Mariana ^a   Traina, Fabíola ^a   Winnischofer, Sheila M ^a   Costa, Fernando F ^a   Queiroz, Mary Luci S ^a   Saad, Sara T Olalla ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Bone marrow microenvironment; Cytokines; Interleukin 10; Myelodysplastic syndromes; Thalidomide

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADULT; AGED; APOPTOSIS; ARTICLE; BONE MARROW CULTURE; CLINICAL ARTICLE; COLONY FORMING UNIT GM; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; GENE EXPRESSION; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC SYSTEM; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; STROMA CELL; SUPERNATANT; UPREGULATION;

ADULT; AGED; ANGIOGENESIS INHIBITORS; BONE MARROW; COCULTURE TECHNIQUES; COLONY-FORMING UNITS ASSAY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMATOPOIETIC STEM CELLS; HUMANS; INTERLEUKIN-10; INTERLEUKIN-1BETA; INTERLEUKIN-6; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STROMAL CELLS; THALIDOMIDE; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79960280273     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.03.027     Document Type: Article

References (38)

1. Bernasconi P. Molecular pathways in myelodysplastic syndromes and acute myeloid leukemia: relationships and distinctions-a review. Br J Haematol 2008, 142:695-708.
2. Raza A., Gezer S., Mundle S., Gao X.Z., Alvi S., Borok R., et al. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 1995, 86:268-276.
3. Parker J.E., Mufti G.J. The role of apoptosis in the pathogenesis of the myelodysplastic syndromes. Int J Hematol 2001, 73:416-428.
4. Corey S.J., Minden M.D., Barber D.L., Kantarjian H., Wang J.C., Schimmer A.D. Myelodysplastic syndromes: the complexity of stem-cell diseases. Nat Rev Cancer 2007, 7:118-129.
5. Gersuk G.M., Beckham C., Loken M.R., Kiener P., Anderson J.E., Farrand A., et al. A role for tumour necrosis factor-alpha, Fas and Fas-ligand in marrow failure associated with myelodysplastic syndrome. Br J Haematol 1998, 103:176-188.
6. Tauro S., Hepburn M.D., Bowen D.T., Pippard M.J. Assessment of stromal function, and its potential contribution to deregulation of hematopoiesis in the myelodysplastic syndromes. Haematologica 2001, 86:1038-1045.
7. Flores-Figueroa E., Gutierrez-Espindola G., Montesinos J.J., Arana-Trejo R.M., Mayani H. In vitro characterization of hematopoietic microenvironment cells from patients with myelodysplastic syndrome. Leuk Res 2002, 26:677-686.
8. Tauro S., Hepburn M.D., Peddie C.M., Bowen D.T., Pippard M.J. Functional disturbance of marrow stromal microenvironment in the myelodysplastic syndromes. Leukemia 2002, 16:785-790.
9. Borojevic R., Roela R.A., Rodarte R.S., Thiago L.S., Pasini F.S., Conti F.M., et al. Bone marrow stroma in childhood myelodysplastic syndrome: composition, ability to sustain hematopoiesis in vitro, and altered gene expression. Leuk Res 2004, 28:831-844.
10. Tennant G.B., Walsh V., Truran L.N., Edwards P., Mills K.I., Burnett A.K. Abnormalities of adherent layers grown from bone marrow of patients with myelodysplasia. Br J Haematol 2000, 111:853-862.
11. Aizawa S., Nakano M., Iwase O., Yaguchi M., Hiramoto M., Hoshi H., et al. Bone marrow stroma from refractory anemia of myelodysplastic syndrome is defective in its ability to support normal CD34-positive cell proliferation and differentiation in vitro. Leuk Res 1999, 23:239-246.
12. Raaijmakers M.H., Mukherjee S., Guo S., Zhang S., Kobayashi T., Schoonmaker J.A., et al. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature 2010, 464:852-857.
13. Ximeri M., Galanopoulos A., Klaus M., Parcharidou A., Giannikou K., Psyllaki M., et al. Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndromes associated with chromosome 5q deletion. Haematologica 2009, 95:406-414.
14. Raza A., Mundle S., Shetty V., Alvi S., Chopra H., Span L., et al. Novel insights into the biology of myelodysplastic syndromes: excessive apoptosis and the role of cytokines. Int J Hematol 1996, 63:265-278.
15. Stifter G., Heiss S., Gastl G., Tzankov A., Stauder R. Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis. Eur J Haematol 2005, 75:485-491.
16. Mundle S.D., Venugopal P., Cartlidge J.D., Pandav D.V., Broady-Robinson L., Gezer S., et al. Indication of an involvement of interleukin-1 beta converting enzyme-like protease in intramedullary apoptotic cell death in the bone marrow of patients with myelodysplastic syndromes. Blood 1996, 88:2640-2647.
17. Aguayo A., Kantarjian H., Manshouri T., Gidel C., Estey E., Thomas D., et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 2000, 96:2240-2245.
18. Bouis D., Kusumanto Y., Meijer C., Mulder N.H., Hospers G.A. A review on pro- and anti-angiogenic factors as targets of clinical intervention. Pharmacol Res 2006, 53:89-103.
19. Bruserud O., Tore Gjertsen B., Brustugun O.T., Bassoe C.F., Nesthus I., Espen Akselsen P., et al. Effects of interleukin 10 on blast cells derived from patients with acute myelogenous leukemia. Leukemia 1995, 9:1910-1920.
20. Bartlett J.B., Dredge K., Dalgleish A.G. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 2004, 4:314-322.
21. Zorat F., Shetty V., Dutt D., Lisak L., Nascimben F., Allampallam K., et al. The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes. Br J Haematol 2001, 115:881-894.
22. Strupp C., Germing U., Aivado M., Misgeld E., Haas R., Gattermann N. Thalidomide for the treatment of patients with myelodysplastic syndromes. Leukemia 2002, 16:1-6.
23. Bowen D., MacIlwaine L., Cavanagh J., Killick S., Culligan D., Thomson E., et al. Thalidomide therapy for low-risk Myelodysplasia. Leuk Res 2005, 29:235-236.
24. Raza A., Meyer P., Dutt D., Zorat F., Lisak L., Nascimben F., et al. Thalidomide produces transfusion independence in long-standing refractory anaemia of patients with myelodysplastic syndromes. Blood 2001, 98:958-965.
25. Gartner S., Kaplan H.S. Long-term culture of human bone marrow cells. Proc Natl Acad Sci USA 1980, 77:4756-4759.
26. Testa N.G., Coutinho L.H., Chang J., Dexter T.M. The biology and use of long-term human bone marrow cultures. The hematopoietic microenvironment. The functional and structural basis of blood cell development 1993, 266-282. John Hopkins University Press, Baltimore. M.W. Long, M.S. Wicha (Eds.).
27. Boula A., Voulgarelis M., Giannouli S., Katrinakis G., Psyllaki M., Pontikoglou C., et al. Effect of cA2 anti-tumor necrosis factor-alpha antibody therapy on hematopoiesis of patients with myelodysplastic syndromes. Clin Cancer Res 2006, 12:3099-3108.
28. Martinez-Jaramillo G., Vela-Ojeda J., Flores-Guzman P., Mayani H. In vitro growth of hematopoietic progenitors and stromal bone marrow cells from patients with multiple myeloma. Leuk Res 2011, 35:250-255.
29. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 2001, 25:402-408.
30. Moore K.W., O'Garra A., de Waal Malefyt R., Vieira P., Mosmann T.R. Interleukin-10. Annu Rev Immunol 1993, 11:165-190.
31. Fiorentino D.F., Zlotnik A., Mosmann T.R., Howard M., O'Garra A. IL-10 inhibits cytokine production by activated macrophages. J Immunol 1991, 147:3815-3822.
32. Westermann F., Kube D., Haier B., Bohlen H., Engert A., Zuehlsdorf M., et al. Interleukin 10 inhibits cytokine production of human AML cells. Ann Oncol 1996, 7:397-404.
33. Klausner J.D., Freedman V.H., Kaplan G. Thalidomide as an anti-TNF-alpha inhibitor: implications for clinical use. Clin Immunol Immunopathol 1996, 81:219-223.
34. D'Amato R.J., Loughnan M.S., Flynn E., Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994, 91:4082-4085.
35. Invernizzi R., Travaglino E., De Amici M., Brugnatelli S., Ramajoli I., Rovati B., et al. Thalidomide treatment reduces apoptosis levels in bone marrow cells from patients with myelodysplastic syndromes. Leuk Res 2005, 29:641-647.
36. Aerbajinai W., Zhu J., Gao Z., Chin K., Rodgers G.P. Thalidomide induces gamma-globin gene expression through increased reactive oxygen species-mediated p38 MAPK signaling and histone H4 acetylation in adult erythropoiesis. Blood 2007, 110:2864-2871.
37. Wagner T., Fritsch G., Thalhammer R., Hocker P., Lanzer G., Lechner K., et al. IL-10 increases the number of CFU-GM generated by ex vivo expansion of unmanipulated human MNCs and selected CD34+ cells. Transfusion 2001, 41:659-666.
38. Koh K.R., Janz M., Mapara M.Y., Lemke B., Stirling D., Dorken B., et al. Immunomodulatory derivative of thalidomide (IMiD CC-4047) induces a shift in lineage commitment by suppressing erythropoiesis and promoting myelopoiesis. Blood 2005, 105:3833-3840.